Skip to content
Screener

BioMarin Pharmaceuticals BMRN Current Debt

Current Debt at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0-100%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$286.94M+5,585%
XER
Xeris Biopharma Holdings, Inc.XERS
$63.78M—
Opko Health logo
Opko HealthOPK
$912K-40.0%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$97K—
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016

FAQ

What is BioMarin Pharmaceuticals's current debt?
BioMarin Pharmaceuticals (BMRN) reported current debt of $658.2M in Q2 2026.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about BioMarin Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude